Scarica l'app Stockscreener
8.91
1.33%
-0.12
Dopo l'orario di chiusura:
8.91
Bridgebio Oncology Therapeutics Inc Borsa (BBOT) Ultime notizie
What date does BridgeBio Oncology Therapeutics, Inc's (BBOT) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Oncology Therapeutics appoints Peter Lebowitz to board of directors - Investing.com Australia
BridgeBio Oncology Therapeutics appoints Peter Lebowitz to board of directors By Investing.com - Investing.com South Africa
BridgeBio Oncology (BBOT) director receives 63,350 stock options award - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) director Peter Lebowitz files initial Form 3 - Stock Titan
63M shares registered for resale by BridgeBio Oncology (NASDAQ: BBOT) - Stock Titan
Bridge appoints Peter Lebowitz to Board, joins NCG and Compensation Committees - TradingView
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) appoints Peter Lebowitz to board - Stock Titan
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform - MSN
BBOT Announces Multiple Presentations at the American - GlobeNewswire
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
CFO equity grants at BridgeBio Oncology Therapeutics (BBOT) - Stock Titan
BBOT (BBOT) Chief Scientific Officer receives new stock options and RSU grants - Stock Titan
BridgeBio Oncology (BBOT) awards stock options and RSUs to chief medical officer - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) and Biohaven Ltd. (BHVN) - The Globe and Mail
BBOT: Three next-gen RAS therapeutics show promising efficacy and safety, with key data due in 2026 - TradingView
BBOT: Lead G12C inhibitor and pan-KRAS assets show strong efficacy with key data expected in late 2026 - TradingView
BBOT publishes preclinical data on panKRAS inhibitor BBO-11818 By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (BBOT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Ardent Health Partners, Inc. (ARDT) - theglobeandmail.com
BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility - TipRanks
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor - Bitget
BBOT Announces Publication in Cancer Discovery Highlighting - GlobeNewswire
Bridgebio Oncology Therapeutics, Inc. Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is Potent and Selective panKRAS Inhibitor - marketscreener.com
Stifel reiterates Buy on BridgeBio Oncology stock, $23 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on BridgeBio Oncology stock, $23 target - Investing.com South Africa
BBOT reports Q4 2025 results, $425M cash runway into 2028 - National Today
BridgeBio Oncology Therapeutics 10-K: Net loss $134.0M, EPS $(4.30) - TradingView
BridgeBio Oncology Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress - The Manila Times
BBOT Technical Analysis & Stock Price Forecast - Intellectia AI
HLXB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BridgeBio Oncology Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BBOT: Novel RAS-targeted therapies show strong efficacy and safety, with major data readouts expected soon - TradingView
BBOT: Major data from three RAS-focused assets expected in H2, highlighting strong efficacy and safety - TradingView
HLXB SEC FilingsHelix Acqsn II 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga Japan
BBOT to Participate in Upcoming Investor Healthcare Conferences - Bitget
Stifel Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy Recommendation - Nasdaq
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on BridgeBio Oncology Therapeutics With Buy Rating, $23 Price Target - marketscreener.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating - Investing.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com India
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):